

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

March 14, 2024

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Ranjana H. Advani, MD

Saul A. Rosenberg Professor of Lymphoma
Division of Oncology
Stanford University School of Medicine
Stanford, California

Mark R. Conaway, PhD

Professor
Division of Translational Research and Applied
Statistics
Department of Public Health Sciences
University of Virginia (UVA) Health System
UVA School of Medicine
Charlottesville, Virginia

Pamela L. Kunz, MD

Associate Professor of Medicine (Oncology)
Division Chief, GI Oncology
Yale School of Medicine and Yale Cancer Center
New Haven, Connecticut

Ravi A. Madan, MD

(Chairperson)
Senior Clinician
Head, Prostate Cancer Clinical Research Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Professor, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

William J. Gradishar, MD

Professor of Medicine/Betsy Bramsen Professor of
Breast Oncology
Chief, Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine at
Northwestern University
Chicago, Illinois

Christopher H. Lieu, MD

Associate Professor of Medicine
Associate Director for Clinical Research
Director, Gastrointestinal Medical Oncology Program
University of Colorado
Aurora, Colorado

David E. Mitchell

(Consumer Representative)
President
Patients for Affordable Drugs
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

March 14, 2024

DRAFT MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Voting) (cont.)

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC)
Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Ashley Rosko, MD

Professor – Clinical Division of Hematology
The Ohio State University (OSU)
Medical Director Oncogeriatric
OSU Comprehensive Cancer Center
Columbus, Ohio

Daniel Spratt, MD

Vincent K Smith Chair, Department of Radiation
Oncology
Professor of Radiation Oncology and Urology
University Hospitals Seidman Cancer Center
Case Western Reserve University
Cleveland, Ohio

Neil Vasan, MD, PhD

Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Tara L. Frenkl, MD, MPH

(Industry Representative)
Senior Vice President, Head of Oncology
Development
Bayer Pharmaceuticals
Whippany, New Jersey

TEMPORARY MEMBERS (Voting)

Jacqueline Garcia, MD

Assistant Professor
Harvard Medical School
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Hunter, MD

Assistant Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Joan D. Powell

(Patient Representative)
Laguna Niguel, California

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

March 14, 2024

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Rick Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Marc Theoret, MD

Deputy Center Director
OCE, OOD, OND, CDER, FDA

R. Angelo de Claro, MD

Division Director
Division of Hematologic Malignancies 1 (DHM1)
OOD, OND, CDER, FDA

Kelly Norsworthy, MD

Deputy Division Director
DHM1, OOD, OND, CDER, FDA

Lori Ehrlich, MD, PhD

Clinical Team Leader
DHM1, OOD, OND, CDER, FDA

Nina Kim, MD

Clinical Reviewer
DHM1, OOD, OND, CDER, FDA